KRAS and colorectal carcinoma: For diagnostic purposes, point mutations of the KRAS gene were most frequently evaluated (n = 25 articles), resulting in sensitivities between 0 and 73% for stage I–IV CRC (32,34,35,41–46,49–53,55–64,115).